Literature DB >> 26075073

Association of polymorphisms and haplotypes in the cytochrome P450 1B1 gene with uterine leiomyoma: A case control study.

Saeedeh Salimi1, Maryam Khodamian2, Mehrnaz Narooie-Nejad3, Azam Hajizadeh2, Kimia Fazeli4, Lida Namazi5, Minoo Yaghmaei5.   

Abstract

Uterine leiomyoma (UL) is an estrogen-dependent neoplasm of the uterus and estrogen metabolizing enzymes affect its promotion and progression. The aim of the present study was to evaluate the association between four single-nucleotide polymorphisms (SNPs) of the cytochrome P450 1B1 (CYP1B1) gene and UL risk. Four SNPs of the CYP1B1 gene in 105 UL patients and 112 unrelated healthy controls were genotyped using a direct sequencing method. Haplotype analyses were performed with UNPHASED software and linkage disequilibrium (LD) was assessed by Haploview software. There were no associations between Leu432Val (rs1056836), Asp449Asp (rs1056837) and Asn453Ser (rs1800440) polymorphisms of the CYP1B1 gene and UL. Although the genotypic frequencies of the Arg368His (rs79204362) polymorphism did not differ between the two groups, the frequency of A (His) allele was significantly higher in UL females (P=0.02). In addition, the frequency of GTAA haplotype was significantly higher in the controls and played a protective role in UL susceptibility. A strong LD between the three common SNPs (rs1056836, rs1056837 and rs1800440) in the CYP1B1 gene was observed in the population. In conclusion, a higher frequency of the CYP1B1 368His (A) allele was observed in UL females. The frequency of the GTAA haplotype was significantly higher in healthy females and this haplotype played a protective role in UL susceptibility.

Entities:  

Keywords:  CYP1B1; gene; haplotype; polymorphism; uterine leiomyoma

Year:  2014        PMID: 26075073      PMCID: PMC4448010          DOI: 10.3892/br.2014.413

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  29 in total

1.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

2.  Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Mark McEvoy; John Attia; Michael Gilbert; Ute Hamann; Rodney J Scott
Journal:  Cancer Epidemiol       Date:  2010-04-08       Impact factor: 2.984

3.  Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers.

Authors:  Marie Stiborová; Václav Martínek; Helena Rýdlová; Tomás Koblas; Petr Hodek
Journal:  Cancer Lett       Date:  2005-04-08       Impact factor: 8.679

Review 4.  Functional role of estrogen metabolism in target cells: review and perspectives.

Authors:  B T Zhu; A H Conney
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

5.  Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium.

Authors:  J Hukkanen; M Mäntylä; L Kangas; P Wirta; J Hakkola; P Paakki; S Evisalmi; O Pelkonen; H Raunio
Journal:  Pharmacol Toxicol       Date:  1998-02

6.  Is genetic polymorphism of ER-α, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma?

Authors:  Gehan A El-Shennawy; Abd-Alla A Elbialy; Anwar E Isamil; Manal M El Behery
Journal:  Arch Gynecol Obstet       Date:  2010-06-18       Impact factor: 2.344

7.  Role of single nucleotide polymorphisms in estrogen-metabolizing enzymes and susceptibility to uterine leiomyoma in Han Chinese: a case-control study.

Authors:  Yang Shen; Qian Xu; Mulan Ren; Yunlang Cai; Jie Xu
Journal:  J Obstet Gynaecol Res       Date:  2013-12-10       Impact factor: 1.730

8.  A multicenter case-control study on screening of single nucleotide polymorphisms in estrogen-metabolizing enzymes and susceptibility to uterine leiomyoma in han chinese.

Authors:  Yang Shen; Mu-Lan Ren; Jie Xu; Qian Xu; Yi-Qian Ding; Zhi-Cong Wu; Hai-Bao Zhang; Xian-Xia Huang; Yun-Lang Cai
Journal:  Gynecol Obstet Invest       Date:  2014-04-23       Impact factor: 2.031

Review 9.  Sex steroidal regulation of uterine leiomyoma growth and apoptosis.

Authors:  T Maruo; N Ohara; J Wang; H Matsuo
Journal:  Hum Reprod Update       Date:  2004 May-Jun       Impact factor: 15.610

10.  Estrogen receptor alpha and beta expression in uterine leiomyomas from premenopausal women.

Authors:  Artur J Jakimiuk; Michal Bogusiewicz; Rafal Tarkowski; Piotr Dziduch; Aneta Adamiak; Andrzej Wróbel; Józef Haczyński; Denis A Magoffin; Jerzy A Jakowicki
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

View more
  5 in total

1.  Association of FAS A-670G Polymorphism and Risk of Uterine Leiomyoma in a Southeast Iranian Population.

Authors:  Abbas Mohammadpour-Gharehbagh; Saeedeh Salimi; Farshid Keshavarzi; Sepideh Zakerian; Mojtaba Sajadian; Mojgan Mokhtari
Journal:  Rep Biochem Mol Biol       Date:  2016-10

2.  Leu/Val SNP polymorphism of CYP1B1 and risk of uterine leiomyoma in a Black population.

Authors:  Virgil S Bideau; Angela T Alleyne
Journal:  Tumour Biol       Date:  2015-10-20

3.  Haplotypes of CYP1B1 and CCDC57 genes in an Afro-Caribbean female population with uterine leiomyoma.

Authors:  Angela T Alleyne; Virgil S Bideau
Journal:  Mol Biol Rep       Date:  2019-04-13       Impact factor: 2.316

4.  Combination effect of cytochrome P450 1A1 gene polymorphisms on uterine leiomyoma: A case-control study.

Authors:  Saeedeh Salimi; Mojtaba Sajadian; Maryam Khodamian; Atefeh Yazdi; Soodabeh Rezaee; Abbas Mohammadpour-Gharehbagh; Mojgan Mokhtari; Minoo Yaghmaie
Journal:  Bosn J Basic Med Sci       Date:  2016-06-22       Impact factor: 3.363

5.  Impact of Genetic Variants in Estrogen Receptor-β Gene in the Etiology of Uterine Leiomyomas.

Authors:  Chitroju Bharathi; Desamala Anupama; Nallari Pratibha; Anantapur Venkateshwari
Journal:  J Reprod Infertil       Date:  2019 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.